Evidence map›Paper›PMID 28830434›Full record

ArticleBiomedical engineering online2017

Rational confederation of genes and diseases: NGS interpretation via GeneCards, MalaCards and VarElect.

Noa Rappaport, Simon Fishilevich, Ron Nudel, Michal Twik, Frida Belinky, Inbar Plaschkes, Tsippi Iny Stein, Dana Cohen, Danit Oz-Levi, Marilyn Safran and 1 more

Abstract read
In one paragraph

Article in Biomedical engineering online, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

49 citing papers in PubMed.

  1. Article
  2. Study ofInternational journal of molecular sciences · 2026
    Article
  3. An Integrative Variant Scoring Function for Finding Novel Genes Associated with Ovarian and Thyroid Cancer.International journal of environmental research and public health · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Multitarget mechanisms of the herb pairFrontiers in pharmacology · 2026
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Drug design, development and therapy · 2025
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Journal of feline medicine and surgery · 2023
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Noa RappaportDepartment of Molecular Genetics, Weizmann Institute of Science, Rehovot, Israel.
Simon FishilevichDepartment of Molecular Genetics, Weizmann Institute of Science, Rehovot, Israel.
Ron NudelDepartment of Molecular Genetics, Weizmann Institute of Science, Rehovot, Israel.
Michal TwikDepartment of Molecular Genetics, Weizmann Institute of Science, Rehovot, Israel.
Frida BelinkyDepartment of Molecular Genetics, Weizmann Institute of Science, Rehovot, Israel.
Inbar PlaschkesDepartment of Molecular Genetics, Weizmann Institute of Science, Rehovot, Israel.
Tsippi Iny SteinDepartment of Molecular Genetics, Weizmann Institute of Science, Rehovot, Israel.
Dana CohenDepartment of Molecular Genetics, Weizmann Institute of Science, Rehovot, Israel.
Danit Oz-LeviDepartment of Molecular Genetics, Weizmann Institute of Science, Rehovot, Israel.
Marilyn SafranDepartment of Molecular Genetics, Weizmann Institute of Science, Rehovot, Israel.
Doron LancetDepartment of Molecular Genetics, Weizmann Institute of Science, Rehovot, Israel. doron.lancet@weizmann.ac.il.

Funding

National Biomedical Information ServicesZIHLM200888 · NLM · NATIONAL LIBRARY OF MEDICINE · PI PALTOO, DINA · 2009 to 2025
$5200.7M
6 · The paper itself

Abstract

backgroundA key challenge in the realm of human disease research is next generation sequencing (NGS) interpretation, whereby identified filtered variant-harboring genes are associated with a patient's disease phenotypes. This necessitates bioinformatics tools linked to comprehensive knowledgebases. The GeneCards suite databases, which include GeneCards (human genes), MalaCards (human diseases) and PathCards (human pathways) together with additional tools, are presented with the focus on MalaCards utility for NGS interpretation as well as for large scale bioinformatic analyses.

resultsVarElect, our NGS interpretation tool, leverages the broad information in the GeneCards suite databases. MalaCards algorithms unify disease-related terms and annotations from 69 sources. Further, MalaCards defines hierarchical relatedness-aliases, disease families, a related diseases network, categories and ontological classifications. GeneCards and MalaCards delineate and share a multi-tiered, scored gene-disease network, with stringency levels, including the definition of elite status-high quality gene-disease pairs, coming from manually curated trustworthy sources, that includes 4500 genes for 8000 diseases. This unique resource is key to NGS interpretation by VarElect. VarElect, a comprehensive search tool that helps infer both direct and indirect links between genes and user-supplied disease/phenotype terms, is robustly strengthened by the information found in MalaCards. The indirect mode benefits from GeneCards' diverse gene-to-gene relationships, including SuperPaths-integrated biological pathways from 12 information sources. We are currently adding an important information layer in the form of "disease SuperPaths", generated from the gene-disease matrix by an algorithm similar to that previously employed for biological pathway unification. This allows the discovery of novel gene-disease and disease-disease relationships. The advent of whole genome sequencing necessitates capacities to go beyond protein coding genes. GeneCards is highly useful in this respect, as it also addresses 101,976 non-protein-coding RNA genes. In a more recent development, we are currently adding an inclusive map of regulatory elements and their inferred target genes, generated by integration from 4 resources.

conclusionsMalaCards provides a rich big-data scaffold for in silico biomedical discovery within the gene-disease universe. VarElect, which depends significantly on both GeneCards and MalaCards power, is a potent tool for supporting the interpretation of wet-lab experiments, notably NGS analyses of disease. The GeneCards suite has thus transcended its 2-decade role in biomedical research, maturing into a key player in clinical investigation.

Indexed as

High-Throughput Nucleotide SequencingComputational BiologyDatabases, GeneticDiseaseGenomicsHumansPhenotype

Identifiers

PMID28830434
PMCPMC5568599

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.